Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Clinical and molecular genetics of the phosphodiesterases (PDEs).

Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F, Manganiello V, Stratakis CA.

Endocr Rev. 2014 Apr;35(2):195-233. doi: 10.1210/er.2013-1053. Epub 2013 Dec 5. Review.

2.

An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.

Gupta R, Kumar G, Kumar RS.

Methods Find Exp Clin Pharmacol. 2005 Mar;27(2):101-18. Review.

PMID:
15834463
3.

Phosphodiesterases in the central nervous system.

Kleppisch T.

Handb Exp Pharmacol. 2009;(191):71-92. doi: 10.1007/978-3-540-68964-5_5. Review.

PMID:
19089326
4.

Therapeutic potential of PDE modulation in treating heart disease.

Knight W, Yan C.

Future Med Chem. 2013 Sep;5(14):1607-20. doi: 10.4155/fmc.13.127. Review.

5.

Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.

Cheng J, Grande JP.

Exp Biol Med (Maywood). 2007 Jan;232(1):38-51. Review.

PMID:
17202584
6.

Advances in targeting cyclic nucleotide phosphodiesterases.

Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC.

Nat Rev Drug Discov. 2014 Apr;13(4):290-314. doi: 10.1038/nrd4228. Review.

7.
8.

Cyclic nucleotide phosphodiesterases (PDEs): coincidence detectors acting to spatially and temporally integrate cyclic nucleotide and non-cyclic nucleotide signals.

Maurice DH, Wilson LS, Rampersad SN, Hubert F, Truong T, Kaczmarek M, Brzezinska P, Freitag SI, Umana MB, Wudwud A.

Biochem Soc Trans. 2014 Apr;42(2):250-6. doi: 10.1042/BST20130268. Review.

PMID:
24646226
9.

The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family.

Gibson LC, Hastings SF, McPhee I, Clayton RA, Darroch CE, Mackenzie A, Mackenzie FL, Nagasawa M, Stevens PA, Mackenzie SJ.

Eur J Pharmacol. 2006 May 24;538(1-3):39-42. Epub 2006 Mar 13.

PMID:
16674936
11.
12.
13.

Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.

Lugnier C.

Pharmacol Ther. 2006 Mar;109(3):366-98. Epub 2005 Aug 15. Review.

PMID:
16102838
15.
16.

Characterization of membrane-bound cyclic nucleotide phosphodiesterases from bovine aortic smooth muscle.

Ivorra MD, Le Bec A, Lugnier C.

J Cardiovasc Pharmacol. 1992 Apr;19(4):532-40.

PMID:
1380595
18.
19.

Cyclic nucleotides and phosphodiesterases and airway function.

Barnes PJ.

Eur Respir J. 1995 Mar;8(3):457-62. Review.

20.
Items per page

Supplemental Content

Write to the Help Desk